Respi-DART 2024 Wataru Sugiura 1/9/25 Respi-DART 2024 Wataru Sugiura 1/9/25 COVID-19 Relapse and Viral Evolution in a Good Syndrome Patient: A Case Study Read More Respi-DART 2024 Nicholas C. Riola 1/9/25 Respi-DART 2024 Nicholas C. Riola 1/9/25 In vitro antiviral activity of obeldesivir and GS-441524 in combination with oral SARS-CoV-2 therapeutics nirmatrelvir/ritonavir or molnupiravir Read More Respi-DART 2024 Mahta Mortezavi 1/9/25 Respi-DART 2024 Mahta Mortezavi 1/9/25 Virologic Response and Safety After Oral Administration of PF-07817883, a Novel SARS-CoV-2 Mpro inhibitor, in Nonhospitalized Adults With Symptomatic COVID-19 Read More Respi-DART 2024 David C. McGowan 1/9/25 Respi-DART 2024 David C. McGowan 1/9/25 Discovery and Preclinical Profile of ALG-097558, a SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 Read More Respi-DART 2024 Andrea Cox 12/24/24 Respi-DART 2024 Andrea Cox 12/24/24 Systems immunology defines immunological profiles associated with long COVID onset and recovery Read More Respi-DART 2024 Vincent Marconi 12/24/24 Respi-DART 2024 Vincent Marconi 12/24/24 Aging from COVID-19 Read More Respi-DART 2024 Dirk Jochmans 12/24/24 Respi-DART 2024 Dirk Jochmans 12/24/24 Inhibitors of SARS-CoV-2 Assembly Read More
Respi-DART 2024 Wataru Sugiura 1/9/25 Respi-DART 2024 Wataru Sugiura 1/9/25 COVID-19 Relapse and Viral Evolution in a Good Syndrome Patient: A Case Study Read More
Respi-DART 2024 Nicholas C. Riola 1/9/25 Respi-DART 2024 Nicholas C. Riola 1/9/25 In vitro antiviral activity of obeldesivir and GS-441524 in combination with oral SARS-CoV-2 therapeutics nirmatrelvir/ritonavir or molnupiravir Read More
Respi-DART 2024 Mahta Mortezavi 1/9/25 Respi-DART 2024 Mahta Mortezavi 1/9/25 Virologic Response and Safety After Oral Administration of PF-07817883, a Novel SARS-CoV-2 Mpro inhibitor, in Nonhospitalized Adults With Symptomatic COVID-19 Read More
Respi-DART 2024 David C. McGowan 1/9/25 Respi-DART 2024 David C. McGowan 1/9/25 Discovery and Preclinical Profile of ALG-097558, a SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 Read More
Respi-DART 2024 Andrea Cox 12/24/24 Respi-DART 2024 Andrea Cox 12/24/24 Systems immunology defines immunological profiles associated with long COVID onset and recovery Read More
Respi-DART 2024 Vincent Marconi 12/24/24 Respi-DART 2024 Vincent Marconi 12/24/24 Aging from COVID-19 Read More
Respi-DART 2024 Dirk Jochmans 12/24/24 Respi-DART 2024 Dirk Jochmans 12/24/24 Inhibitors of SARS-CoV-2 Assembly Read More